Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Resectable stage I to III non-small-cell lung cancer, drawn from the whole corpus: 57 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether adjuvant immunotherapy adds anything after neoadjuvant treatment and surgery, especially for complete pathological responders, has not been tested directly.
Circulating tumour DNA after surgery identifies high-risk patients but no trial yet shows that acting on it improves survival.
About a fifth of patients given neoadjuvant therapy never reach surgery, from progression, toxicity or decline.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Screening uptake is low in most countries, so most lung cancers are still found late.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 20 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
Perioperative NSCLC (KEYNOTE-671)
DFS HR 0.
5-year disease-free survival 63.
EFS HR 0.